• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial
Publication date: 24–30 August 2019Source: The Lancet, Volume 394, Issue 10199Author(s): Gholamreza Roshandel, Masoud Khoshnia, Hossein Poustchi, Karla Hemming, Farin Kamangar, Abdolsamad Gharavi, Mohammad Reza Ostovaneh, Alireza Nateghi, Masoud Majed, Behrooz Navabakhsh, Shahin Merat, Akram Pourshams, Mahdi Nalini, Fatemeh Malekzadeh, Masoumeh Sadeghi, Noushin Mohammadifard, Nizal Sarrafzadegan, Mohammad Naemi-Tabiei, Abdolreza Fazel, Paul BrennanSummaryBackgroundA fixed-dose combination therapy (polypill strategy) has been proposed as an approach to reduce the burden of cardiovascular disease, especially in low-income ...
Source: The Lancet - August 23, 2019 Category: General Medicine Source Type: research

Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials
Publication date: 2–8 February 2019Source: The Lancet, Volume 393, Issue 10170Author(s): Jane Armitage, Colin Baigent, Elizabeth Barnes, D John Betteridge, Lisa Blackwell, Michael Blazing, Louise Bowman, Eugene Braunwald, Robert Byington, Christopher Cannon, Michael Clearfield, Helen Colhoun, Rory Collins, Björn Dahlöf, Kelly Davies, Barry Davis, James de Lemos, John R Downs, Paul Durrington, Jonathan EmbersonSummaryBackgroundStatin therapy has been shown to reduce major vascular events and vascular mortality in a wide range of individuals, but there is uncertainty about its efficacy and safety among older people. We u...
Source: The Lancet - February 2, 2019 Category: General Medicine Source Type: research

Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials
This study provides a rationale for testing the lipoprotein(a) lowering hypothesis in cardiovascular disease outcomes trials.FundingNovartis Pharma AG.
Source: The Lancet - October 5, 2018 Category: General Medicine Source Type: research

Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial
Publication date: Available online 26 August 2018Source: The LancetAuthor(s): Ajay Gupta, Judith Mackay, Andrew Whitehouse, Thomas Godec, Tim Collier, Stuart Pocock, Neil Poulter, Peter SeverSummaryBackgroundIn patients with hypertension, the long-term cardiovascular and all-cause mortality effects of different blood pressure-lowering regimens and lipid-lowering treatment are not well documented, particularly in clinical trial settings. The Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy Study reports mortality outcomes after 16 years of follow-up of the UK participants in the original ASCOT trial.MethodsASCOT was...
Source: The Lancet - August 26, 2018 Category: General Medicine Source Type: research

Interpretation of the evidence for the efficacy and safety of statin therapy
Publication date: Available online 8 September 2016 Source:The Lancet Author(s): Rory Collins, Christina Reith, Jonathan Emberson, Jane Armitage, Colin Baigent, Lisa Blackwell, Roger Blumenthal, John Danesh, George Davey Smith, David DeMets, Stephen Evans, Malcolm Law, Stephen MacMahon, Seth Martin, Bruce Neal, Neil Poulter, David Preiss, Paul Ridker, Ian Roberts, Anthony Rodgers, Peter Sandercock, Kenneth Schulz, Peter Sever, John Simes, Liam Smeeth, Nicholas Wald, Salim Yusuf, Richard Peto This Review is intended to help clinicians, patients, and the public make informed decisions about statin therapy for the prevention...
Source: The Lancet - September 8, 2016 Category: Journals (General) Source Type: research

Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data
Publication date: Available online 20 October 2015 Source:The Lancet Author(s): Rasha Khatib, Martin McKee, Harry Shannon, Clara Chow, Sumathy Rangarajan, Koon Teo, Li Wei, Prem Mony, Viswanathan Mohan, Rajeev Gupta, Rajesh Kumar, Krishnapillai Vijayakumar, Scott A Lear, Rafael Diaz, Alvaro Avezum, Patricio Lopez-Jaramillo, Fernando Lanas, Khalid Yusoff, Noorhassim Ismail, Khawar Kazmi, Omar Rahman, Annika Rosengren, Nahed Monsef, Roya Kelishadi, Annamarie Kruger, Thandi Puoane, Andrzej Szuba, Jephat Chifamba, Ahmet Temizhan, Gilles Dagenais, Amiram Gafni, Salim Yusuf Background WHO has ta...
Source: The Lancet - October 23, 2015 Category: Journals (General) Source Type: research

Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials
Publication date: Available online 9 January 2015 Source:The Lancet Background Whether statin therapy is as effective in women as in men is debated, especially for primary prevention. We undertook a meta-analysis of statin trials in the Cholesterol Treatment Trialists' (CTT) Collaboration database to compare the effects of statin therapy between women and men. Methods We performed meta-analyses on data from 22 trials of statin therapy versus control (n=134 537) and five trials of more-intensive versus less-intensive statin therapy (n=39 612). Effects on major vascular events, major coronary events, stroke, coronary re...
Source: The Lancet - January 9, 2015 Category: Journals (General) Source Type: research